Last reviewed · How we verify

Metolazone Oral Tablet

University of Virginia · FDA-approved active Small molecule

Metolazone inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron, promoting urinary excretion of water and electrolytes.

Metolazone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron, promoting urinary excretion of water and electrolytes to reduce blood volume and blood pressure. Used for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.

At a glance

Generic nameMetolazone Oral Tablet
Also known asZaroxolyn
SponsorUniversity of Virginia
Drug classThiazide-like diuretic
TargetNa-Cl cotransporter (NCC)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

As a thiazide-like diuretic, metolazone blocks the Na-Cl cotransporter in the kidney's distal tubule, reducing blood volume and sodium levels. This leads to decreased peripheral vascular resistance and lower blood pressure. It is particularly effective in patients with reduced renal function where other thiazides may be less effective.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: